Table 1—

Demographic, anthropometric, cardiovascular, humoral, and clinical parameters of the study patients

Type 1 diabetes
Type 2 diabetes
P value
Male subjectsFemale subjectsAllMale subjectsFemale subjectsAll
n3173216383,9113,9487,859
Age (years)47 ± 1750 ± 1848 ± 1764 ± 1166 ± 1165 ± 11<0.0001
Duration of disease (years)15 ± 1117 ± 1216 ± 1110 ± 8.011 ± 8.010 ± 8.0<0.0001
BMI (kg/m2)24.8 ± 3.625.0 ± 5.524.9 ± 4.628.4 ± 4.330.0 ± 5.629.2 ± 5.1<0.0001
Waist (cm)89 ± 1384 ± 1687 ± 1599 ± 1398 ± 1598 ± 14<0.0001
Fasting plasma glucose (mmol/l)10 ± 4.39.6 ± 3.79.8 ± 4.08.8 ± 2.89.0 ± 2.88.9 ± 2.8<0.0001
A1C (%)7.9 ± 1.78.0 ± 1.58.0 ± 1.67.5 ± 1.97.7 ± 1.57.6 ± 1.7<0.0001
Creatinine (μmol/l)87 ± 5388 ± 5388 ± 5388 ± 4489 ± 5288 ± 440.287
Systolic blood pressure (mmHg)132 ± 18130 ± 19131 ± 19141 ± 18143 ± 18142 ± 18<0.0001
Diastolic blood pressure (mmHg)79 ± 1078 ± 9.979 ± 1082 ± 9.782 ± 1082 ± 9.8<0.0001
LDL cholesterol (mmol/l)2.9 ± 0.93.0 ± 1.02.9 ± 0.93.2 ± 0.93.3 ± 1.03.2 ± 0.9<0.0001
HDL cholesterol (mmol/l)1.3 ± 0.31.4 ± 0.41.4 ± 0.41.2 ± 0.31.3 ± 0.31.2 ± 0.3<0.0001
Triglycerides (mmol/l)1.5 ± 0.81.4 ± 1.01.4 ± 0.91.9 ± 1.01.8 ± 0.91.9 ± 1.0<0.0001
AHA/NHLBI metabolic syndrome (%)24.543.233.758.880.869.5<0.0001
IDF metabolic syndrome (%)34.147.640.869.585.677.6<0.0001
  • Continuous variables are means ± SD. P values refer to the comparison between type 1 and type 2 diabetic patients. Prevalence of IDF-defined metabolic syndrome was significantly higher (P < 0.01) than prevalence of AHA/NHLBI-defined metabolic syndrome in both types of diabetes.